Back to INSM Overview
NMS · Valuation Lab
INSM
Insmed Incorporated
Last$99.02
Market cap21.5B
EV/EBITDA-22.1x
Intrinsic value
$18.02
MoS -449.6% · Overvalued
Assuming 15.0% FCF margin and 10.0% Y1–5 growth.
Upside to price
EV (DCF)3.4B
Terminal share63%
Expected IV$18.95
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 63% of EV
PV of stage FCFs1.3B
PV of terminal value2.2B
Enterprise value3.4B
Net cash / (debt)481.1M
Equity value3.9B
Intrinsic value / share$18.02
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 901.5M | 135.2M | 125.2M | 92.6% |
| Y2 | 991.7M | 148.8M | 127.4M | 85.7% |
| Y3 | 1.1B | 163.6M | 129.7M | 79.3% |
| Y4 | 1.2B | 180M | 132.1M | 73.4% |
| Y5 | 1.3B | 198M | 134.5M | 67.9% |
| Y6 | 1.4B | 207.9M | 130.7M | 62.9% |
| Y7 | 1.5B | 218.3M | 127M | 58.2% |
| Y8 | 1.5B | 229.2M | 123.5M | 53.9% |
| Y9 | 1.6B | 240.7M | 120M | 49.9% |
| Y10 | 1.7B | 252.7M | 116.6M | 46.1% |
| Terminal | — | — | 2.2B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.